Cargando…

Fragile X targeted pharmacotherapy: lessons learned and future directions

Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erickson, Craig A., Davenport, Matthew H., Schaefer, Tori L., Wink, Logan K., Pedapati, Ernest V., Sweeney, John A., Fitzpatrick, Sarah E., Brown, W. Ted, Budimirovic, Dejan, Hagerman, Randi J., Hessl, David, Kaufmann, Walter E., Berry-Kravis, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467059/ https://www.ncbi.nlm.nih.gov/pubmed/28616096 http://dx.doi.org/10.1186/s11689-017-9186-9

Ejemplares similares

Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
por: Luu, Skylar, et al.
Publicado: (2020)

Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018)

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome
por: Budimirovic, Dejan B., et al.
Publicado: (2017)

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

Genomic studies in fragile X premutation carriers
por: Lozano, Reymundo, et al.
Publicado: (2014)

Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
por: Lee, Anna W., et al.
Publicado: (2018)

Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome
por: Hessl, David, et al.
Publicado: (2019)

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2022)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization
por: Cordeiro, Lisa, et al.
Publicado: (2010)

Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities
por: Weber, Jayne Dixon, et al.
Publicado: (2019)

Drosophila melanogaster as a Model to Study Fragile X-Associated Disorders
por: Trajković, Jelena, et al.
Publicado: (2022)

Emerging pharmacologic treatment options for fragile X syndrome
por: Schaefer, Tori L, et al.
Publicado: (2015)

Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study
por: Hong, Michael P., et al.
Publicado: (2019)

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment
por: Protic, Dragana D., et al.
Publicado: (2022)

Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
por: Albizua, Igor, et al.
Publicado: (2022)

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
por: Berry-Kravis, E, et al.
Publicado: (2009)

Aggression in autism spectrum disorder: presentation and treatment options
por: Fitzpatrick, Sarah E, et al.
Publicado: (2016)

Examination of Correlates to Health-Related Quality of Life in Individuals with Fragile X Syndrome
por: Coffman, Marika C., et al.
Publicado: (2020)

Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome
por: Farzin, Faraz, et al.
Publicado: (2011)

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
por: Palumbo, Joseph M., et al.
Publicado: (2023)

Fragile X Syndrome: Lessons Learned from the Most Translated Neurodevelopmental Disorder in Clinical Trials
por: Duy, Phan Q., et al.
Publicado: (2017)

The challenges of clinical trials in fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2013)

Fragile X Premutation
por: Tassone, Flora, et al.
Publicado: (2014)

Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study
por: Budimirovic, Dejan B., et al.
Publicado: (2021)

Raising Knowledge and Awareness of Fragile X Syndrome in Serbia, Georgia, and Colombia: A Model for Other Developing Countries?
por: Protic, Dragana, et al.
Publicado: (2021)

A neurophysiological model of speech production deficits in fragile X syndrome
por: Schmitt, Lauren M, et al.
Publicado: (2019)

Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives
por: Lozano, Reymundo, et al.
Publicado: (2022)

Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome
por: Schmitt, Lauren M., et al.
Publicado: (2022)

Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome
por: Famula, Jessica, et al.
Publicado: (2022)

Feasibility, reliability, and clinical validity of the Test of Attentional Performance for Children (KiTAP) in Fragile X syndrome (FXS)
por: Knox, Andrew, et al.
Publicado: (2012)

Fragile X Syndrome: Recent Research Updates toward Capturing Treatments’ Improvement in Clinical Trials
por: Budimirovic, Dejan B., et al.
Publicado: (2022)

Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome
por: Chonchaiya, Weerasak, et al.
Publicado: (2010)

The Relationship between Expressive Language Sampling and Clinical Measures in Fragile X Syndrome and Typical Development
por: Shaffer, Rebecca C., et al.
Publicado: (2020)

Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome
por: Ethridge, Lauren E., et al.
Publicado: (2017)

Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study
por: Brašić, James Robert, et al.
Publicado: (2022)

A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments
por: Budimirovic, Dejan B., et al.
Publicado: (2020)

Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance
por: Ethridge, Lauren E., et al.
Publicado: (2019)

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents
por: Hagerman, Randi, et al.
Publicado: (2018)

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments
por: Hagerman, Randi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_0uphq84jit5cvj4q3t0bfq5b9g